Evaluation consideration for clinical research and development of URAT1 inhibitors for gout
Gout is a crystal-related arthropathy caused by the deposition of monosodium urate(MSU)in the joints,which is directly related to hyperuricemia caused by purine metabolism disorders and/or reduced uric acid excretion.With the continuous improvement of people's material living standard and the intake of more and more purine-containing foods,the prevalence of gout is increasing year by year.Currently,commonly used urate-lowering drugs in China include two categories:drugs inhibiting uric acid synthesis(allopurinol and febuxostat)and that promoting uric acid excretion(benbromarone).Although existing drugs can reduce gout attacks and the burden of gout,it has certain limitations and new effective and safe gout treatment drugs need to be developed.Currently,URAT1-targeted drug design is a hot topic in the research and development of anti-gout drugs.This paper reviewed the current status of clinical application of URAT1 inhibitors.Regarding the increasing number of applications for clinical trials of URAT1 varieties,combined with the relevant problems encountered in the evaluation,we also discussed the design and evaluation consideration for clinical trials of URAT1 inhibitors,so as to improve the research and development and provide references for researchers.
gouturate transporter 1 inhibitorclinical research and developmentevaluation consideration
NETL
NSTL
万方数据
